Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide/formoterol/glycopyrrolate - AstraZeneca

Drug Profile

Budesonide/formoterol/glycopyrrolate - AstraZeneca

Alternative Names: BGF MDI; Breztri Aerosphere; Budesonide/formoterol fumarate/glycopyrronium; Budesonide/glycopyrrolate/formoterol; Budesonide/glycopyrronium/formoterol fumarate; Budesonide/PT 003; Formoterol/budesonide/glycopyrrolate; Formoterol/glycopyrrolate/budesonide; Formoterol/glycopyrronium bromide/budesonide; Glycopyrrolate/budesonide/formoterol; Glycopyrrolate/formoterol/budesonide; LAMA/LABA/ICS triple combination; LAMA/LABA/ICS-triple-combination-therapy; PT-003/budesonide; PT-010; Riltrava Aerosphere; Trixeo Aerosphere

Latest Information Update: 12 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pearl Therapeutics
  • Developer AstraZeneca; Pearl Therapeutics
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antispasmodics; Antiulcers; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Pyrrolidines; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase III Asthma

Most Recent Events

  • 12 Mar 2024 AstraZeneca plans a phase I trial for Chronic Obstructive Pulmonary Disease (In adults) in Germany and United Kingdom (Inhalation) in April 2024 (NCT06297668)
  • 28 Feb 2024 AstraZeneca plans a phase III THARROS trial for Chronic obstructive pulmonary disease in the US, Argentina, Australia, Austria, Brazil, Bulgaria, Canada, Chile, China, Colombia, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Malaysia, Mexico, Norway, Peru, Philippines, Poland, Romania, Serbia, Spain, Sweden, Taiwan, Thailand, Turkey and the United Kingdom (Inhalation) in February 2024 (NCT06283966)
  • 21 Feb 2024 Phase-III clinical trials in Chronic obstructive pulmonary disease (In adults, In the elderly) in USA, Canada (Inhalation)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top